Table 5.

Randomized phase II studies of S-1 based chemotherapy after gemcitabine failure

Ref.	Treatment group	n	ORR	PFS (mo)	MST (mo)
Mizuno et al[36]	S-1 + irinotecan	60	18.3%	107 d	208 d
	S-1	67	6.0%a	58 d	176 d
Okusaka et al[37]	S-1 + oxaliplatin	134	20.9%	3.0	7.5
	S-1	130	11.5%a	2.8	7.0
Okusaka et al[38]	S-1 + leucovorin	69	27.5%	3.8	6.3
	S-1	71	19.7%	2.7b	6.1

^aP < 0.05 vs S-1;

^bP < 0.01 vs S-1. PFS: Progression-free survival; MST: Median survival time; ORR: Objective response rate.